Immuneering Reaffirms First-Line Pancreatic Cancer Focus Following FDA Nod For Rasonque
(RTTNews) - Immuneering (IMRX), a late-stage clinical oncology company, issued a statement highlighting its focus on the first-line metastatic pancreatic cancer setting following the FDA's approval of Revolution Medicines' (RVMD) Rasonque ( …